Search details
1.
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.
J Gen Intern Med
; 2024 Feb 06.
Article
in English
| MEDLINE | ID: mdl-38321315
2.
Regulating Laboratory Tests: What Framework Would Best Support Safety and Validity?
Milbank Q
; 2024 May 13.
Article
in English
| MEDLINE | ID: mdl-38738445
3.
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Ann Intern Med
; 176(8): 1047-1056, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37549393
4.
Moving Naloxone Over the Counter Is Necessary but Not Sufficient.
Ann Intern Med
; 176(8): 1109-1112, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37459615
5.
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence.
Ann Intern Med
; 176(9): 1251-1256, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37603868
6.
Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis.
Ann Intern Med
; 176(11): 1508-1515, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37871317
7.
Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.
Ann Intern Med
; 176(10): 1413-1418, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37844306
8.
Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
JAMA
; 2024 May 20.
Article
in English
| MEDLINE | ID: mdl-38767878
9.
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.
JAMA
; 331(17): 1471-1479, 2024 05 07.
Article
in English
| MEDLINE | ID: mdl-38583175
10.
Federal Enforcement of Pharmaceutical Fraud under the False Claims Act, 2006-2022.
J Health Polit Policy Law
; 49(2): 249-268, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-37801012
11.
Approval and therapeutic value of gene therapies in the US and Europe.
Gene Ther
; 30(10-11): 756-760, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37935853
12.
Medicaid Spending on Antiretrovirals From 2007 Through 2019.
Clin Infect Dis
; 76(5): 833-841, 2023 03 04.
Article
in English
| MEDLINE | ID: mdl-36268585
13.
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.
PLoS Med
; 20(3): e1004190, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36877723
14.
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.
PLoS Med
; 20(11): e1004309, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37971985
15.
Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
Value Health
; 26(3): 370-377, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36266218
16.
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.
JAMA
; 329(15): 1283-1289, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-37071095
17.
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
JAMA
; 330(7): 650-657, 2023 08 15.
Article
in English
| MEDLINE | ID: mdl-37505513
18.
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process.
J Health Polit Policy Law
; 48(5): 799-820, 2023 10 01.
Article
in English
| MEDLINE | ID: mdl-36995365
19.
Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Lancet Oncol
; 23(4): 514-520, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35271804
20.
Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
Clin Infect Dis
; 74(2): 347-351, 2022 01 29.
Article
in English
| MEDLINE | ID: mdl-33914860